Celltrion’s ‘Remsima’ acquired the Australian approval
Celltrion announced on the 10th that the company has acquired approval for Remsima from the Australian food and drug ministry, TGA(Therapeutic Goods Administration).
The TGA is expected to apply the same indication and health insurance benefit as the original drug on Remsima. The Australian TNF-...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
